Senores Pharmaceuticals Limited (“SPL”), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (“SPI”), has signed agreements today to acquire a basket of 14 Abbreviated New Drug Applications (‘ANDAs’) from Dr. Reddy’s Laboratories and its applicable affiliates (BSE: 500124 | NSE: DRREDDY | NYSE: RDY |
Senores Pharmaceuticals Limited (‘Senores’ or ‘SPL’) has today inaugurated and commenced manufacturing activities at its greenfield Active Pharmaceutical Ingredient (API) plant located at Survey No. 1503, Rajpur, Kadi, Mehsana - 382 715, Gujarat. Spread across approximately 230,000 sq. ft. with an installed capacity of ~100 Metric
Senores Pharmaceuticals Limited (‘SPL’), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (‘SPI’), has signed an agreement today to acquire the USFDA-approved Abbreviated New Drug Application (‘ANDA’) for ‘Roflumilast’ 250 mcg and 500 mcg tablets from Breckenridge Pharmaceutical, Inc., a U.S. subsidiary of Towa International
Senores Pharmaceuticals Ltd. has reported revenue of ₹288 Cr during 9MFY25 ending 31st December,2024, reflecting a robust growth of 157%. The exceptional financial performance underscores the company’s strong business strategies and operational excellence. Key Highlights Total Revenue is 288 Cr which is 157% increase PAT after
